Videos

Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.

Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.

Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.

Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.

Douglas Tremblay, MD, discusses the use and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Francis P. Worden, MD, discusses the efficacy findings from the phase 3 COSMIC-311 study of cabozantinib in thyroid cancer.

Edward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the enrollment criteria and dosing for the phase 3 KEYNOTE-A18 study of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Manmeet Ahluwalia, MD, discusses the future initiatives of the Cancer Moonshot program.

Leticia Nogueira, PhD, MPH, discusses how healthcare professionals and patients can come together facing the threats of climate change on cancer care.

Manmeet Ahluwalia, MD, discusses the implications of the Cancer Moonshot program for community oncologists.

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.

Dr Atkins discusses current unmet needs in the treatment landscape for metastatic melanoma and provides an overview of some of the treatments currently under investigation that show promise.

Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.

Immune-related adverse events are often a sign treatment is working. Dr Atkins discusses potential adverse events and how he counsels patients about them.

An expert perspective on how to best treat a patient diagnosed with stage IV BRAF-mutated melanoma.

Dr Atkins shares his approach to first-line treatment and reviews data regarding treatment sequencing from the DREAMseq Trial.

An overview of treatments for metastatic melanoma, including data updates regarding combination options.

Michael B Atkins, MD, shares insights on the prognosis of patient’s diagnosed with advanced melanoma and discusses the value of BRAF mutation testing.

Naval G. Daver, MD, discusses the unmet needs that still exist in the treatment of acute myeloid leukemia.

Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.

Leticia Nogueira, PhD, MPH, discusses the vulnerabilities and hazards that patients with cancer experience due to climate change.

Naval G. Daver, MD, discusses how stem cell transplants factor into the current treatment landscape of acute myeloid leukemia.

Leticia Nogueira, PhD, MPH, discusses the cancer risks that fossil fuel consumption and climate change present.

Josh Weitz, MD, discusses how to balance cost-savings and efficiency while maximizing patient satisfaction in his medical practice.

Joshua Richter, MD, talks about the barriers to diversity in oncology clinical trials.

Thoracic oncologists discuss the progress made and unmet needs that remain in the non–small cell lung cancer treatment space.

Medical oncologists discuss where antibody-drug conjugates fit in the overall non–small cell lung cancer treatment landscape and review the ongoing EVOKE-01 and EVOKE-03 clinical trials.

Naval Daver, MD, discusses the evolution in the treatment of acute myeloid leukemia for both older and younger patient populations.